16 completed. 16 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 16 |
Follow Severe Dengue: new trials by email Literature Review of Severe Dengue trials Research Report on Severe Dengue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant, Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant, Phosphate buffered saline - Dengue Fever | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 100 | 2012-11-01 | 2017-05-23 |
| A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults 4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline - Dengue Fever | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 100 | 2012-09-01 | 2019-01-25 |
| Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 112 | 2011-08-01 | 2015-08-20 |
| Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3 - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 141 | 2010-07-01 | 2013-01-03 |
| Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Investigational Vaccine for DEN1, Placebo injection - Dengue Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2010-04-01 | 2013-01-03 |
| Safety and Immune Response to an Investigational Dengue Type 2 Vaccine Investigational Vaccine for Dengue Virus Subtype 2, Placebo - Dengue Virus | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2010-02-01 | 2013-01-03 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults rDEN3delta30/31-7164 - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2009-09-01 | 2013-11-15 |
| Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus DEN4 Vaccine Candidate, DEN4 Vaccine Placebo - Dengue Shock Syndrome, Dengue Hemorrhagic Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 70 | 2009-07-01 | 2013-01-03 |
| Study of HBV-001 D1 in Healthy Adults DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel), Placebo for DEN1-80E - Dengue Fever | Phase 1 | Completed | Hawaii Biotech, Inc. | 16 | 2009-07-01 | 2011-02-07 |
| Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine rDEN1delta30, Placebo - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2007-05-01 | 2010-01-13 |
| Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus rDEN1delta30, rDEN2/4delta30(ME), Placebo to rDEN1delta30 or rDEN2/4delta30(ME) - Dengue Hemorrhagic Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 36 | 2007-03-01 | 2010-12-14 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults rDEN4delta30-4995, Placebo - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 84 | 2007-01-01 | 2009-08-07 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults rDEN3/4delta30(ME), Placebo - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 58 | 2006-10-01 | 2010-12-14 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults rDEN4delta30-200,201, Placebo - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2006-06-01 | 2013-01-03 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults rDEN2/4delta30(ME) Vaccine, Placebo - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 28 | 2005-01-01 | 2008-01-21 |
| Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults rDEN1delta30, Placebo - Dengue Fever | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 28 | 2004-09-01 | 2008-01-18 |
Dengue (14)
Arbovirus Infections (16) · Flaviviridae Infections (16) · Flavivirus Infections (16) · Hemorrhagic Fevers, Viral (16) · Infections (16) · Mosquito-Borne Diseases (16) · RNA Virus Infections (16) · Vector Borne Diseases (16) · Virus Diseases (16) · Dengue (2)
Aluminum Hydroxide (3) · Vaccines (2) · Biological Products (1)
National Institute of Allergy and Infectious Diseases (NIAID) (13) · U.S. Army Medical Research and Development Command (2) · Hawaii Biotech, Inc. (1)
United States (15) · Puerto Rico (1)
Anna Durbin, MD (12) · Beth Kirkpatrick, MD (2) · Beth-Ann Coller, PhD (1) · Clemente Diaz, MD (1) · Kawsar Talaat, MD (1) · Leyi Lin, MD (1)
PMID 25801652, PMID 26383952, PMID 21208923, PMID 23329850, PMID 26458804, PMID 28719287, PMID 29512481, PMID 30010906, PMID 32394880